TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of hidradenitis suppurativa (HS) for at least 1 year prior to Baseline.~* Total abscess and inflammatory nodule (AN) count of ≥ 5 at Baseline, presence of HS lesions in at least 2 distinct anatomical areas, and draining fistula count of ≤ 20 at Baseline.~* History of inadequate response or an intolerance to adequate trial of oral antibiotics for treatment of HS.~* Required to use a daily antiseptic wash on HS lesions.~Exclusion Criteria:~-History of active skin disease (other than HS) that could interfere with assessment of HS, including skin infections requiring systemic treatment within 4 weeks of the Baseline visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Upadacitinib 30 mg (Type: EXPERIMENTAL): Participants will receive 30 mg upadacitinib orally once a day for 12 weeks (Period 1) followed by 30 mg upadacitinib orally once a day for 36 weeks (Period 2).
- Placebo followed by Upadacitinib 15 mg (Type: EXPERIMENTAL): Participants will receive matching placebo orally once a day for 12 weeks (Period 1) followed by 15 mg upadacitinib orally once a day for 36 weeks (Period 2).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05690 (Care Program) (P05710)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participants who participated in base study P05690 (NCT00702845) and received at least one dose of either corifollitropin alfa (Org 36286) or recFSH in base study P05690;~* Ongoing pregnancy confirmed by ultrasound at least 10 weeks after embryo transfer in base study P05690;~* Able and willing to give written informed consent.~Exclusion Criteria:~* None

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 36 Years
- Healthy Volunteers: f

Study Arms:
- Corifollitropin alfa 100 μg (Type: None): In follow-up study, no medication or investigational product was administered. In base study P05690 (NCT00702845), participants received single subcutaneous (SC) injection of corifollitropin alfa 100 μg (Org 36286) on Day 2 or 3 of menstrual cycle and daily placebo-recombinant Follicle Stimulating Hormone (recFSH) injections (7 total) from Stimulation Day 1 up to and including Stimulation Day 7. Participants in base study P05690 also received open-label recFSH (up to 200 IU/day) from Stimulation Day 8 onwards, up to and including Day of Human Chorion Gonadotropin (hCG) administration. Participants also received Gonadotropin Releasing Hormone (GnRH) antagonist ganirelix (0.25 mg) once daily SC starting on Stimulation Day 5 up to and including Day of hCG (10,000 or 5,000 IU/USP). Participants also received progesterone (at least 600 mg/day vaginally or 50 mg/day by intramuscular \[IM\] injection), starting on day of oocyte pick-up (OPU) and continuing for at least 6 weeks or up to menses.
- recFSH 150 IU (Type: None): In follow-up study, no medication or investigational product was administered. In base study P05690 (NCT00702845), participants in the reference group received a single SC injection of placebo-corifollitropin alfa administered on Day 2 or 3 of the menstrual cycle and daily SC recFSH 150 IU injections (7 total) from Stimulation Day 1 up to and including Stimulation Day 7. Participants also received open-label recFSH (up to 200 IU/day) from Stimulation Day 8 onwards, up to and including Day of hCG (10,000 or 5,000 IU/USP) administration. Participants also received the GnRH antagonist ganirelix (0.25 mg) once daily SC starting on Stimulation Day 5 up to and including the Day of hCG. Participants also received progesterone (at least 600 mg/day vaginally or 50 mg/day IM), starting on the day of OPU and continuing for at least 6 weeks or up to menses.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prostatic Artery Embolization Versus Medical Treatment in Symptomatic Benign Prostatic Hyperplasia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men aged\>= 50 and \<=85 years AND~* Moderate to severe LUTS defined as IPSS \> 11, and QoL \> 3 AND~* No improvement after an alpha blocker treatment line (Tamsulosin 0.4 mg p.d. during 1 month) AND~* Prostatic volume \>=50 ml AND~* Affiliated to a French health insurance system~Exclusion Criteria:~* Severe allergy to iodine contrast agent~* Treatment with 5-ARI on the last 6 months~* Suspected prostate cancer requiring specific management~* On-going prostatitis~* On-going urinary retention~* On-going acute urinary infection~* Acontractile detrusor~* Neurogenic lower urinary tract dysfunction~* Urethral stenosis~* Bladder diverticulum~* Bladder stone with surgical indication~* Patient refusing PAE~* Creatinine clearance \<40 ml/min~* Severe liver failure~* Contra-indication to alpha-blockers~* Hypersensitivity to dutasteride, other 5-alpha reductase inhibitors, tamsulosin (including case of tamsulosin induced angioedema), soya, peanut or one of the excipients~* Hypersensitivity to gelatin or collagen~* Patients ineligible for pelvic angiography~* History of orthostatic hypotension~* Patient unable or unwilling to provide written informed consent~* Patient under legal protection

- Gender: MALE
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Embolization (Type: EXPERIMENTAL): Prostatic Arteries Embolization
- Combined Therapy (Type: ACTIVE_COMPARATOR): Combodart® : dutasteride 0.5 mg/tamsulosin 0.4 mg per day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Efficacy and Safety of add-on Alpha-lipoic Acid on Migraine Prophylaxis in Adolescent Population

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with 15 or more headache days per month with at least 8 days having migraine features for at least 3 months (according to the criteria of the International Classification of Headache Disorders, 3rd edition \[beta version\], or ICHD-3 beta).~* Adolescent migraineurs aged 10 to 19 years of age of either sex.~* Patients who have not taken any prophylactic treatment within the last three months before their inclusion in the study.~* Patients and/or parents have given informed written consent/assent.~Exclusion Criteria:~* Patient with headache other than migraine.~* Patients who were on corticosteroids~* Treatment with any test drugs in the preceding three months from the start of the trial.~* If there is any history of interventions or devices used for the treatment of migraine, such as transcranial magnetic stimulation and nerve blocks during the 3 months before screening.~* Any other accompanying systemic illness; abnormalities revealed on neurologic examination.~* Psychiatric disturbances, history of epilepsy , learning disabilities, head trauma or use of other drugs acting on the central nervous system, including, smoking, alcohol consumption or any illicit drug abuse

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 19 Years
- Healthy Volunteers: f

Study Arms:
- Flunarizine (Type: ACTIVE_COMPARATOR): flunarizine will be prescribed at a dose of 5mg once daily , orally for 12 weeks
- Alpha Lipoic Acid (Type: EXPERIMENTAL): Alpha Lipoic Acid will be prescribed at a dose of 300mg once daily,orally for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-333 and Ribavirin (RBV) in Treatment-Naïve and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic hepatitis C virus (HCV)~* Treatment naive, null or partial responders to previous treatment with peginterferon and ribavirin~* Males and females 18-65 years old~* Body mass index 18 to \< 35 kg/m\^2~* Females must be postmenopausal for at least 2 years or surgically sterile~Exclusion Criteria:~* Cirrhosis or extensive bridging fibrosis~* History of cardiac disease~* Positive screen for certain drugs or alcohol~* Abnormal laboratory results~* Significant sensitivity to any drug~* Positive hepatitis B surface antigen or anti-human immunodeficiency virus antibody~* Use of strong cytochrome P450 3A (CYP3A), cytochrome P450 2C8 (CYP2C8), and organic anion transporting polypeptide 1B1 (OATP1B1) enzyme inducers or inhibitors within 1 month of dosing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- ABT-450/r (250/100 mg) and ABT-333 plus RBV in treatment-naïve (Type: EXPERIMENTAL): ABT-450/r (250/100 mg) once daily (QD) and ABT-333 (400 mg) twice daily (BID) plus weight-based ribavirin (RBV) divided BID for 12 weeks in treatment-naïve participants.
- ABT-450/r (150/100 mg) and ABT-333 plus RBV in treatment-naïve (Type: EXPERIMENTAL): ABT-450/r (150/100 mg) once daily (QD) and ABT-333 (400 mg) twice daily (BID) plus weight-based ribavirin (RBV) divided BID for 12 weeks in treatment-naïve participants.
- ABT-450/r (150/100 mg) and ABT-333 plus RBV in non-responders (Type: EXPERIMENTAL): ABT-450/r (150/100 mg) once daily (QD) and ABT-333 (400 mg) twice daily (BID) plus weight-based ribavirin (RBV) divided BID in previous non-responders to pegylated interferon (pegIFN) and RBV.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Novel Use Of Hydroxyurea in an African Region With Malaria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pediatric subjects with documented sickle cell anemia (HbSS supported by hemoglobin electrophoresis or by peripheral blood smear showing sickled red blood cells)~* Age range of 1.00-3.99 years, inclusive, at the time of enrollment~* Weight at least 5.0 kg at the time of enrollment~* Willingness to comply with all study-related treatments, evaluations, and follow up~Exclusion Criteria:~* Known chronic medical condition (e.g., HIV, malignancy, active clinical tuberculosis)~* Severe malnutrition determined by impaired growth parameters as defined by WHO (weight for length/height or weight-for-length/height \> 3 z-scores below the median WHO growth standards)~* Pre-existing severe hematological toxicity:~  1. Hb \<4.0 g/dL~ 2. Hb \<6.0 g/dL AND ARC \<100 x 10E9/L~ 3. Hb \<7.0 g/dL AND ARC \<80 x 10E9/L~ 4. Platelets \<80 x 10E9/L~ 5. ANC \<1.0 x 10E9/L~* Alanine transaminase (ALT) or creatinine \>2 times the upper limit of normal for age~* Blood transfusion within 30 days prior to enrollment

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 47 Months
- Healthy Volunteers: f

Study Arms:
- Hydroxyurea (Type: EXPERIMENTAL): Fixed dose 20 ± 2.5 mg/kg/day, administered once a day in tablet form (100mg or scored 1000mg) for twelve months
- Placebo (Type: PLACEBO_COMPARATOR): Fixed dose 20 ± 2.5 mg/kg/day, administered once a day in tablet form (100mg or scored 1000mg) for twelve months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Effect of Lansoprazole on Infants With Gastroesophageal Reflux Disease.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Hospitalized or outpatient male or female, term or post-term infants beyond the neonatal period (\>28 days) but less than 12 months of age, OR a preterm infant with a corrected age of at least 44 weeks but less than 12 months on Dosing Day 1.~* Clinically-evident Gastroesophageal Reflux Disease (feeding intolerance, regurgitation, wheezing or stridor with feedings)~* At least 7 days post-surgery without anticipated need for surgery during study~* No significant laboratory abnormalities~Exclusion Criteria:~* Unstable, clinically significant disease or abnormality~* Congenital anomaly of the upper gastrointestinal tract~* Clinical evidence of acute sepsis~* Cystic fibrosis~* Medical condition requiring subject to not be fed by mouth/gastric tube

- Gender: ALL
- Minimum Age: 29 Days
- Maximum Age: 364 Days
- Healthy Volunteers: f

Study Arms:
- Lansoprazole 1.0 mg/kg QD (Type: EXPERIMENTAL): None
- Lansoprazole 2.0 mg/kg QD (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparing Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec and Insulin Glargine 300 U/mL at Steady-state Conditions in Subjects With Type 1 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female aged 18-64 years (both inclusive) at the time of signing informed consent~* Subjects diagnosed (clinically) with type 1 diabetes mellitus at least 365 days prior to the day of screening~* Body mass index 18.5-29.0 kg/m\^2 (both inclusive)~Exclusion Criteria:~* Subject who has donated any blood or plasma in the past month or more than 500 mL within 3 months prior to screening~* Smoker (defined as a subject who is smoking more than 5 cigarettes or the equivalent per day)who is not able or willing to refrain from smoking or use of nicotine gum or transdermal nicotine patches during the in-patient period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- IDeg (Type: EXPERIMENTAL): None
- IGlar U300 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Optimizing Soft Speech Recognition in Children With Hearing Loss

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* native English speakers who communicate verbally~* no known speech language disorders, cognitive or learning issues~* experienced hearing aid users (\> 6 months use)~* full-time hearing aid users (i.e., wear on a daily basis)~* CNC word scores of 30% or better at 50dBA in quiet with SE off~Exclusion Criteria:~* new hearing aid users~* inconsistent hearing aid users~* \<4 years or \>12 years of age~* non-native English speaker who communicates verbally~* known cognitive/ learning issues or speech language disorder~* CNC word scores \< 30% correct presented at 50dBA in quiet with SE off

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Children with Hearing Loss (Type: EXPERIMENTAL): Participants age 5-12 with hearing loss who will be fit with study hearing aids and tested on speech perception in unaided and aided condition.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Obese Patients With Untreated Dyslipidemias

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
* BMI must be greater than 27 and less than 40~* Patients with untreated dyslipidemia~* Stable weight (variation of less than 5 kg within 3 months prior to screening visit)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced Constipation In Patients With Advanced Illness

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Is an adult 18 years of age or older~* Has a diagnosis of advanced illness (ie, a terminal illness such as incurable cancer or other end-stage disease)~* Has a life expectancy of at least 1 month.~* Is receiving opioids on a regular schedule (not just as-needed or rescue doses) for the control of pain or discomfort for at least 2 weeks before the first dose of study drug.~* Has constipation that is caused by opioid medications.~Exclusion Criteria:~* Has a known or suspected allergy to methylnaltrexone or other similar compounds (e.g. naltrexone or naloxone).~* Has a known or suspected mechanical gastrointestinal obstruction.~* Has any potential nonopioid cause of bowel dysfunction that might be a major contributor to the constipation.~* Has any other clinically important abnormalities as determined by the investigator that may interfere with his or her participation in or compliance with the study.~* Receiving opioid antagonist or partial antagonist products.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Methylnaltrexone (Type: EXPERIMENTAL): Methylnaltrexone subcutaneously every other day for 14 days (ie, 7 doses). Subjects received 0.6 mL (12 mg) every other day if weight ≥ 62kg; or 0.4 mL (8 mg) every other day if weight between 38 and \<62 kg. Subjects with impaired kidney function received reduced doses according to instructions in the Relistor prescribing information.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo subcutaneously every other day for 14 days (ie, 7 doses). Subjects received 0.6 mL every other day if weight ≥ 62kg; or 0.4 mL every other day if weight between 38 and \< 62 kg. Subjects with impaired kidney function received reduced volumes of placebo solution to match the volumes used in the experimental group.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Therapeutic Effect of Tacrolimus on Primary Nephrotic Syndrome in Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Frequent relapse nephrotic syndrome~* steroid resistance nephrotic syndrome~Exclusion Criteria:~* secondary nephrotic syndrome~* estimated glomerular filtration rate \< 60 mL/min/1.73m2~* with active hepatitis

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: t

Study Arms:
- Tacrolimus (Type: EXPERIMENTAL): Tacrobell

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* The study cohort from which cases and controls are drawn is all subjects in the UK GPRD 1993-2008. Entry into the study cohort begins Jan 1, 1993 for all those who are registered in GPRD before that time, and at the time of registration if later than Jan 1, 1993. Follow-up ends Dec 31, 2008, or earlier if the respective cancer is diagnosed, or if the subject leaves the GPRD for any reason including death.~Exclusion Criteria:~* Cases and controls will be required to have at least 2 years of follow-up in the study cohort before their index date (For cases, the index date is the date of first diagnosis of the respective cancer. The index date for controls is set as the date at which the follow-up time from cohort entry is the same as the case.)

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- UK GPRD 1993-2008 (Type: None): The study cohort from which cases and controls are drawn is all subjects in the United Kingdom (UK) General Practice Research Database (GPRD) 1993-2008. Each member of the UK population is registered with a General Practice, which centralizes the medical information not only from the general practitioners themselves but also from specialist referrals and hospital attendances. Over 487 General Practices contribute data to the GPRD. Entry into the study cohort begins Jan 1, 1993 for all those who are registered in GPRD before that time, and at the time of registration if later than Jan 1, 1993.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete